Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Managing cardiotoxicity in anthracycline-treated breast cancers.

Ng R, Green MD.

Expert Opin Drug Saf. 2007 May;6(3):315-21. Review.

PMID:
17480180
2.

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.

Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T.

Ann Oncol. 2008 Sep;19(9):1530-9. doi: 10.1093/annonc/mdn292. Epub 2008 May 13. Review.

3.

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.

Gianni L, Salvatorelli E, Minotti G.

Cardiovasc Toxicol. 2007;7(2):67-71. Review.

PMID:
17652806
4.

Cardiac safety of liposomal anthracyclines.

Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):161-81. Review.

PMID:
15717742
5.

Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).

Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S.

Breast. 2009 Aug;18(4):218-24. doi: 10.1016/j.breast.2009.05.004. Epub 2009 Aug 4. Review.

PMID:
19656681
6.
7.

[Cardiotoxicity of conservative treatment of solid tumors].

Sivak LA, Askol'skiĭ AV, Lial'kin SA, Klimanov MIu, Maĭdanevich NN, Kasap NV.

Lik Sprava. 2011 Apr-Jun;(3-4):51-9. Review. Russian.

PMID:
22416364
8.

Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.

Jensen BV.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S15-21. Review.

PMID:
16781285
9.

Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.

Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A.

Tumori. 2011 Nov-Dec;97(6):690-2. doi: 10.1700/1018.11082. Review.

10.

Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?

Kaklamani VG, Gradishar WJ.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S26-33. Review.

PMID:
12756076
11.

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

van Dalen EC, Michiels EM, Caron HN, Kremer LC.

Cochrane Database Syst Rev. 2010 May 12;(5):CD005006. doi: 10.1002/14651858.CD005006.pub4. Review.

PMID:
20464735
12.

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

van Dalen EC, Michiels EM, Caron HN, Kremer LC.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005006. doi: 10.1002/14651858.CD005006.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(5):CD005006.

PMID:
20238335
13.
14.

Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.

O'Brien ME.

Anticancer Drugs. 2008 Jan;19(1):1-7. Review.

PMID:
18043124
15.

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

van Dalen EC, Michiels EM, Caron HN, Kremer LC.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005006. Review. Update in: Cochrane Database Syst Rev. 2010;(3):CD005006.

PMID:
17054231
16.

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.

Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A, Verrill MW.

Ann Oncol. 2009 May;20(5):816-27. doi: 10.1093/annonc/mdn728. Epub 2009 Jan 19. Review.

17.

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.

Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE.

Expert Opin Pharmacother. 2007 Jun;8(8):1039-58. Review.

PMID:
17516870
18.

Cardiotoxic effects of trastuzumab.

Hysing J, Wist E.

Tidsskr Nor Laegeforen. 2011 Nov 15;131(22):2239-41. doi: 10.4045/tidsskr.10.0862. Review. English, Norwegian.

19.

Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

Rahman AM, Yusuf SW, Ewer MS.

Int J Nanomedicine. 2007;2(4):567-83. Review.

20.

[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].

Nagykálnai T.

Magy Onkol. 2010 Dec;54(4):359-67. doi: 10.1556/MOnkol.54.2010.4.10. Review. Hungarian.

Items per page

Supplemental Content

Write to the Help Desk